Gland Pharma adds investor meetings for June 04, 2026

1 min read     Updated on 30 May 2026, 11:48 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Gland Pharma Limited has updated its schedule for meetings with analysts and institutional investors in June 2026. The company added new sessions with BofA and Emkay Global for June 04, 2026, supplementing previously announced interactions with Carnelian Asset Management and ICICI Securities later in the month. The schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

powered bylight_fuzz_icon
41337433

*this image is generated using AI for illustrative purposes only.

Gland Pharma Limited has updated its schedule for meetings with analysts and institutional investors in June 2026. The company added new sessions with BofA and Emkay Global for June 04, 2026, supplementing previously announced interactions with Carnelian Asset Management and ICICI Securities later in the month.

The updated schedule includes a group meeting arranged by BofA and a one-on-one session with Emkay Global. These additions follow the earlier disclosed plan to host Carnelian Asset Management for a one-on-one meeting and participate in the ICICI Securities India Investor Conference 2026.

The company noted that the schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

The following table outlines the confirmed schedule:

Date Investor/Analyst/Fund Name Type of Meeting
June 01, 2026 Carnelian Asset Management One-on-One Meeting
June 04, 2026 Group Meeting arranged by BofA Group Meeting
June 04, 2026 Emkay Global One-on-One Meeting
June 08, 2026 ICICI Securities India Investor Conference 2026 One-on-One & Group Meetings

Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the intimation on May 29, 2026.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.96%-3.28%+27.50%+26.40%+38.50%-29.36%

What key topics or strategic updates is Gland Pharma likely to discuss during these investor meetings?

How might these investor interactions influence Gland Pharma's stock performance in the near term?

Could the increased engagement with analysts signal upcoming corporate actions or new business developments?

Gland Pharma Records Multiple NSE Block Trades Across Four Deals

0 min read     Updated on 26 May 2026, 01:43 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Gland Pharma witnessed four significant block trades on the NSE, with individual trade values of ₹30.06 crores, ₹27.52 crores, ₹40.07 crores, and ₹22.91 crores. The transactions covered approximately 129,196, 118,121, 172,720, and 99,326 shares at prices ranging from ₹2307.00 to ₹2330.00 per share, reflecting substantial institutional activity in the stock.

powered bylight_fuzz_icon
40798147

*this image is generated using AI for illustrative purposes only.

Gland Pharma witnessed multiple significant block trades on the National Stock Exchange (NSE), spanning four separate transactions. The trades involved approximately 129,196 shares, 118,121 shares, 172,720 shares, and 99,326 shares, executed at prices of ₹2326.50, ₹2330.00, ₹2319.90, and ₹2307.00 per share, respectively.

Block Trade Details

The following table summarises the key parameters of all four block trades recorded on the NSE:

Parameter: Trade 1 Trade 2 Trade 3 Trade 4
Exchange: NSE NSE NSE NSE
Number of Shares: ~129,196 ~118,121 ~172,720 ~99,326
Trade Price: ₹2326.50 per share ₹2330.00 per share ₹2319.90 per share ₹2307.00 per share
Total Trade Value: ₹30.06 crores ₹27.52 crores ₹40.07 crores ₹22.91 crores

Block trades of this scale are typically associated with institutional investors or large stakeholders executing bulk transactions outside the regular market order book, and serve as a key indicator of significant interest in the stock at the traded price levels.

Historical Stock Returns for Gland Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.96%-3.28%+27.50%+26.40%+38.50%-29.36%

What impact will these block trades have on Gland Pharma's stock price in the short term?

Who are the institutional investors or stakeholders behind these large transactions?

Could this signal a change in ownership structure or strategic direction for the company?

More News on Gland Pharma

1 Year Returns:+38.50%